Targeting CD11b+ myeloid cells or SERPINB3 both reduced tumor growth, however, the latter in combination with RT demonstrated more sustained inhibition of tumor growth and remodeling of infiltrating myeloid cells. This evidence concerns the gene ITGAM and neoplasm.